Erasca (ERAS) Interest Expenses (2020 - 2026)
Erasca's (ERAS) quarterly Interest Expenses came in at $672.8 million in Q1 2026, up 44752.4% YoY from N/an in Q1 2025, and up 44752.4% on a QoQ basis from $1.5 million in Q4 2025.
Analysis
Erasca (ERAS) Interest Expenses (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Interest Expenses data on file, last reported at $672.8 million in Q1 2026.
- Quarterly Interest Expenses rose 44752.4% year-over-year to $672.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $672.8 million (up 102658.84% YoY) and the FY2025 annual result came in at $242.2 million, up 1764.65% from the prior year.
- Interest Expenses climbed to $672.8 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $672.8 million in Q1 2026 to a low of -$4.5 million in Q4 2023.
- A 5-year average of $65.5 million and a median of $16.7 million in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses tumbled 826.99% — and 2026, when it jumped 44752.4%.
- Tracing ERAS's Interest Expenses over 5 years: stood at $615000.0 in 2022, then plunged by 826.99% to -$4.5 million in 2023, then jumped by 138.02% to $1.7 million in 2024, then dropped by 11.76% to $1.5 million in 2025, then jumped by 44752.4% to $672.8 million in 2026.
- The last three Interest Expenses figures came in at $672.8 million (Q1 2026), $1.5 million (Q4 2025), and $16.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Erasca | 5.02 Bn | 5.02 Bn | - | 63,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 63,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Jun 30, 2024 | 460,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Dec 31, 2023 | 67,000.00 |
| Sep 30, 2023 | 49,000.00 |
| Jun 30, 2023 | 62,000.00 |
| Mar 31, 2023 | 51,000.00 |
| Dec 31, 2022 | 50,000.00 |
| Sep 30, 2022 | 49,000.00 |
| Jun 30, 2022 | 91,000.00 |
| Mar 31, 2022 | 67,000.00 |
| Sep 30, 2021 | 74,000.00 |
| Jun 30, 2021 | 61,000.00 |
| Mar 31, 2021 | 55,000.00 |
| Sep 30, 2020 | 38,000.00 |
| Jun 30, 2020 | 33,000.00 |